NeurOdys Therapeutics Launches to Advance Small Molecule Treatments for Neurodegenerative Diseases
Amsterdam, Netherlands – Torrey Pines Investment announced the launch of NeurOdys Therapeutics with pre-seed funding led by NLC Health Ventures and Rambam AG, a Swiss-based venture studio and a part of the Expert Systems accelerator platform. NeurOdys Therapeutics, headquartered in Amsterdam, is a biotechnology company focused on developing innovative small molecule therapies for neurodegenerative disorders, including Alzheimer's and Parkinson’s diseases.
NeurOdys Therapeutics brings together a world-class team of scientists, drug development experts, and seasoned industry professionals dedicated to advancing disease-modifying treatments. Leveraging advanced computational modeling, AI-driven drug discovery platforms, and proprietary technologies, NeurOdys is well-positioned to expedite the development of therapeutics designed to significantly enhance patient outcomes.
"With the support from Rambam AG and NLC Health Ventures, as well as strategic backing from Torrey Pines Investment, we are uniquely positioned to rapidly advance therapies that could profoundly impact the treatment of neurodegenerative diseases," said Dr. Vasily Kazey, CEO of NeurOdys Therapeutics.
About Rambam AG
Rambam AG is a Swiss-based venture studio and accelerator platform for breakthrough drug discovery and development. Rambam diversified portfolio of companies and programs is supported by a core group of seasoned industrial experts, key opinion leaders and dedicated functional experts from Switzerland, Netherlands, Portugal, Germany and the US.
About NLC Health Ventures
Based out of Amsterdam, NLC Health Ventures is the most active health technology investor in Europe and the world’s largest healthtech venture builder. NLC finds, builds, and scales transformative health innovations to provide more patients with quality care. NLC is ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17. With more than 100 startups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale. The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s startups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding.
About Torrey Pines Investment
Torrey Pines Investment, based in San Diego, CA, has focused on early to development-stage breakthrough medicines since 2002. Its therapeutic interests include oncology, neurodegenerative disorders, cardiovascular diseases, and more.
Media contact:
Vasily Kazey
CEO
vkazey@neurodysther.com